Statistically significant reductions in food noise scores from baseline were observed in adults taking semaglutide injection within the first month of initiation and through six months in the SIGNAL study1
Oral semaglutide was associated with about a 25% reduction from baseline in reported average food noise scores over three months in the OCTANE study. Most adults (86.4%) reported at least one treatment improvement2
Food noise is an emerging area of research in obesity care, with real-world studies suggesting semaglutide may provide an additional patient-centered benefit beyond weight loss
Today, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek® 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy® injection or Wegovy® pill.1,2 Both retrospective cohort analyses used de-identified patient data from the Ro telehealth platform and a validated seven-item questionnaire to assess food noise, defined as persistent, intrusive and unwanted thoughts about food.
“Patients at our center often describe persistent and intrusive thoughts about food, and that managing those thoughts can take a toll on their day-to-day lives,” said Louis J. Aronne, MD, Director of the Comprehensive Weight Control Center, Weill Cornell Medicine, and co-author of the studies. “The SIGNAL and OCTANE findings showed that semaglutide injection and oral semaglutide were associated with early reductions in food noise in real-world studies. Looking forward, additional research can help clarify the clinical relevance of such food noise and its place in everyday obesity care”
The two presented studies examined changes in patient-reported food noise scores over time among adults with overweight or obesity taking semaglutide in a real-world telehealth setting, using the validated seven-item Ro Allison Indiana Dhurandhar–Food Noise Inventory (RAID-FN) questionnaire, which measures persistent, intrusive and unwanted thoughts about food.1,2
In the SIGNAL study, 26,213 treatment-naïve adults with obesity or overweight with at least one weight-related condition initiating semaglutide injection were followed for up to six months in a real-world telehealth setting.1 The adjusted mean baseline RAID-FN total score was 2.72 (95% CI 2.71, 2.74).1 Mean food noise scores decreased within the first month, with an adjusted mean change from baseline of -0.42 points (95% CI -0.43, -0.41).1 The greatest reductions were observed during the first three months, and reductions were maintained through month 6, when the adjusted mean change from baseline was -0.72 points (95% CI: -0.74 to -0.70
In the OCTANE study, adults initiating oral semaglutide reported a statistically significant reduction in average food noise scores over 3 months, reducing by ~25% from baseline (total RAID-FN score 2.8 to 2.1 (p<0.001)).2 At program entry, participants’ most commonly reported treatment goals were to lose weight (98.0%), improve general physical health (76.5%), and increase confidence in their appearance (54.5%).¹ Participants also commonly reported weight-related impacts on confidence, clothing, sense of self and energy.2 At three months, 86.4% reported at least one treatment improvement, including better-fitting clothing (67.5%), healthier eating (51.6%), more physical activity (26.8%), more energy during the day (26.6%), improved mood (21.7%), fewer alcohol cravings (18.8%) and better sleep 18.6%

“As GLP-1 medicines, like Wegovy®, become more widely used and discussed, many people have asked about their impact on food noise as they think about treatment,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “While food noise remains an emerging area of research, at Novo, we are working to advance the science of obesity and broaden understanding beyond changes on the scale. These real-world findings from the SIGNAL and OCTANE studies, conducted in partnership with Ro, contribute to our efforts to better understand the lived experiences of people with obesity and the outcomes they say matter to them”
Real-world evidence can complement randomized controlled trials, which are the gold standard for evaluating a treatment’s safety and efficacy.4 Real-world studies evaluate associations and cannot determine causality. Limitations of the SIGNAL and OCTANE studies include: variable timing and completeness of data being collected during routine telehealth care; potential bias associated with self-reported data; possible selection bias resulting from the treatmentpersistence requirement; and limited generalizability to the broader population
It is important to note that semaglutide injection 2.4 mg and semaglutide tablets 25 mg contain a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in those with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss









اترك تعليقاً